As the globalization of clinical trials continues, the major CROs are expanding their operations in Asia and South America.
In January 2013, Charles River Laboratories acquired a 75% ownership of Vital River, a commercial provider of research models
and related services in China. For the past 10 years, Vital River has been a licensee for production and distribution of Charles
River's research models in China. The agreement provides an option for Charles River to acquire the remaining 25% of Vital
River at a later date. As part of the Vital River acquisition, Charles River will be the exclusive global partner for distribution
of model-creation services offered through Beijing Vital Star Biotechnology. The services of Beijing Vital Star Biotechnology
include humanized model creation using inducible pluripotent stem cell and other technologies.
In June 2012, Quintiles announced its plans to establish a Quintiles regional headquarters for China in Shanghai and expand
laboratory-testing capabilities in China, which includes a partnership with Shanghai Clinical Research Center (SCRC). Under
a joint-venture agreement, Quintiles will engage SCRC to provide laboratory-testing services to local customers. Founded under
the collaborative framework of the Ministry of Science and Technology and Shanghai Municipality in 2008, SSCRC is a full-service
clinical research center in China. To provide the infrastructure for its growth strategy in China, Quintiles is investing
$14 million to establish a new 4000-m2 headquarters in Shanghai to serve China and nearby Asian countries. The facility is expected to accommodate more than 450
employees in the next five years. The Quintiles–SCRC collaboration follows the 2011 launch of Kun Tuo, a Quintiles' CRO that
serves local and global biopharmaceutical companies in achieving successful registration of medicines in China. Quintiles
began operations in China in 1997 and now has existing offices in Beijing, Dalian, Hong Kong, and Shanghai.
Quintiles is expanding elsewhere in Asia. In October 2012, Quintiles began its first global study involving Indonesia, made
possible by an exclusive alliance with Prodia Clinical Laboratory for in-country testing of samples from Indonesian patients
in clinical trials. In an Oct., 24, 2012, press release, Quintiles noted prior to its partnership with Prodia that Indonesia
had been difficult to include in global trials because of requirements that all local samples be tested in-country before
samples or data could be exported. In November 2011, Quintiles announced an exclusive partnership with the Jakarta-based Prodia
Clinical Laboratory, through its sister company Prodia, which gave Quintiles exclusive access to Prodia's central laboratory
for a two-year period.
To enhance its bioanalytical service offerings in Asia, Quintiles formed, in December 2012, an exclusive partnership with
BioCore, a Seoul, Korea-based bioanalytical CRO. BioCore is a provider of bioanalytical liquid chromatography–tandem mass
spectrometry. Under the agreement, BioCore will provide its services to Quintiles exclusively for a two-year period. Quintiles'
growing global bioanalytical capabilities began with its acquisition of Advion BioServices in 2011. In July 2012, Quintiles
opened a global commercial solutions business in Brazil. Quintiles had earlier expanded its global commercial solutions business
into Russia, the Middle East, and North Africa.
In 2012, Covance reported that its early-development facility in Shanghai, China received a good laboratory practice certificate
from China's State Food and Drug Administration. The Covance facility in Shanghai provides nonclinical safety assessment,
bioanalytical, in vivo pharmacology, and drug metabolism and pharmacokinetics (DMPK) services. Covance opened the facility in August 2010.
PAREXEL opened a customer-care office in Shanghai in December 2012 for Perceptive Informatics, a subsidiary of PAREXEL and
eClinical solutions provider. In November 2012, PAREXEL formed an alliance with the National Taiwan University Hospital to
provide drug-development services in Taiwan. Earlier in 2012, PAREXEL was chosen by the Korea Drug Development Fund (KDDF)
to serve as the fund's CRO. The KDDF is a consortium of three health-related Korean ministries: the Ministry of Knowledge
Economy, the Ministry of Education, Science and Technology, and the Ministry of Health and Welfare. KDDF was established in
September 2011 with assets of $1 billion to develop at least 10 new drugs by 2019 for the global market. The alliance with
KDDF follows PAREXEL's 2012 collaborative research agreement with the ASAN Medical Center based in Seoul.
In October 2012, ICON and the Korea National Enterprise for Clinical Trials (KoNECT) formed a partnership to advance the clinical-trials
industry in South Korea. Through the agreement, ICON and KoNECT will collaborate on a series of educational events for local
and multinational pharmaceutical companies, investigators, and industry officials. KoNECT was established in 2007 with the
support of the South Korean government, academic institutions, and life-science industries to provides clinical-research resources,
training, and support.
In February 2012, ICON completed its acquisition of BeijingWits Medical Consulting, a CRO in China with staff located in Beijing,
Shanghai, Chengdu, Guangzhou, Wuhan, and Hong Kong. The company provides services for Phase I to Phase IV clinical studies
to global and local pharmaceutical, medical device, and biotechnology companies. Also, in 2012, INC Research opened a facility
in Seoul, South Korea. INC Research provides Phase I to IV clinical development services in the Asia/Pacific region with coverage
across China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand, and New Zealand.
The CROs WuXi PharmaTech and PRA signed a joint-venture agreement in December 2012 to offer a broad platform of Phase I–IV
clinical trial services in China, Hong Kong, and Macau. The joint venture will provide services, including clinical-trial
monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug-safety reporting,
and medical monitoring. The clinical operations of WuXi and PRA in China will combine to operate as an independent CRO and
will be jointly owned by their respective parent companies. WuXi will contribute clinical and regulatory experience to the
joint venture from its China-based clinical organization. That organization covers all regions of the country and has employees
working in 16 Chinese cities, with offices in Shanghai, Beijing, and Guangzhou. WuXi also will supply laboratory services
to the joint venture through a preferred-provider arrangement. PRA will support the joint venture on with its global expertise
and staffing and with its China-based staff and global technology capabilities, encompassing data capture, trial management,
and other information-technology systems. The companies will market the joint venture's services to their respective customers.
In February 2012, PRA also opened an office in Singapore for PRA's central clinical operations location for the region.